Celsion Corporation (CLSN) Fall to $2.30

Celsion Corporation (NASDAQ:CLSN) Corporate Logo

Celsion Corporation (NASDAQ:CLSN) decreased considerably to $2.30. It was posted on Mar, 15 by Barchart.com. Celsion Corporation (NASDAQ:CLSN) has $43.08M MC. The valuation of NASDAQ:CLSN can change by $3.02M if our $2.14 PT is touched.

On March, 26 Celsion Corporation (NASDAQ:CLSN)’s earnings release is expected by WallStreet, Zacks reports. 34.62 % negative EPS growth is what analysts predict. $-0.26 earnings per share was announced for last quarter.

For more Celsion Corporation (NASDAQ:CLSN) news announced briefly go to: Globenewswire.com, Seekingalpha.com, Seekingalpha.com, Globenewswire.com or Globenewswire.com. The titles are as follows: “Celsion Announces Progression-Free Survival Data From GEN-1 Phase I Immuno-Oncology Study of Patients with Stage III/IV Ovarian Cancer – GlobeNewswire” announced on October 24, 2018, “Celsion: A Great Asymmetric Trade – Seeking Alpha” on March 08, 2018, “Celsion net loss improves in Q3 – Seeking Alpha” with a publish date: November 15, 2018, “Celsion Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) – GlobeNewswire” and the last “Celsion Corporation Announces Strategic Loan Facility Nasdaq:CLSN – GlobeNewswire” with publication date: June 28, 2018.

Celsion Corporation, an oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer.The firm is worth $43.08 million. The companyÂ’s lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer.Currently it has negative earnings. It is also developing GEN-1, a DNA immunotherapeutic product for the localized treatment of ovarian and brain cancers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.